Table 4. Table depicting the site, intent, lines of treatment and drugs used.
| Site | Intent | Line of treatment | Drugs |
|---|---|---|---|
| Head and neck | Palliative | 1st line, 2nd line and beyond | Nivolumab Pembrolizumab |
| NSCLC | Palliative | 1st line, 2nd line and beyond | Nivolumab Nivolumab + Ipilimumab Pembrolizumab Atezolizumab |
| NSCLC | Curative | - | Durvalumab |
| SCLC | Palliative | 1st line | Atezolizumab |
| Oesophagus | Palliative | 2nd line and beyond | Nivolumab |
NSCLC, Non-small cell lung cancer; SCLC, Small cell lung cancer